Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TRPV1 | Q8NER1 | 2/20 | 0.56 |
| ▸ | THRB | P10828 | 1/20 | 0.52 |
| ▸ | NAMPT | P43490 | 4/20 | 0.51 |
| ▸ | HDAC1 | Q13547 | 2/20 | 0.49 |
| ▸ | HDAC2 | Q92769 | 1/20 | 0.49 |
| ▸ | ABCB1 | P08183 | 2/20 | 0.47 |
| ▸ | ABCG2 | Q9UNQ0 | 2/20 | 0.47 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.47 |
| ▸ | POLB | P06746 | 1/20 | 0.46 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.46 |
| ▸ | TAAR1 | Q96RJ0 | 1/20 | 0.46 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.45 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.44 |
| ▸ | NPC1 | O15118 | 2/20 | 0.43 |
| ▸ | RAB9A | P51151 | 2/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL978679 | 0.85 | HDAC1 (0.42) | TRPV1THRBHDAC1HDAC2ABCB1 | |
| SCHEMBL978322 | 0.82 | THRB (0.50) | TRPV1THRBNAMPTHDAC1HDAC2 | |
| SCHEMBL13822826 | 0.81 | HDAC2 (0.47) | HDAC1HDAC2NPC1RAB9A | |
| SCHEMBL976881 | 0.81 | THRB (0.49) | TRPV1THRBNAMPTHDAC1HDAC2 | |
| SCHEMBL976805 | 0.81 | NAMPT (0.52) | TRPV1THRBNAMPTHDAC1HDAC2 | |
| SCHEMBL975548 | 0.81 | PDGFRB (0.49) | HDAC1HDAC2SMN1; SMN2NPC1RAB9A | |
| SCHEMBL977442 | 0.79 | NAMPT (0.51) | TRPV1THRBNAMPTHDAC1HDAC2 | |
| SCHEMBL975340 | 0.76 | F10 (0.47) | TRPV1THRBNAMPTHDAC1HDAC2 | |
| SCHEMBL29370405 | 0.76 | ALDH1A1 (0.74) | TRPV1THRBNAMPTL3MBTL1ALDH1A1 | |
| SCHEMBL975723 | 0.74 | PDGFRB (0.51) | NAMPTHDAC1HDAC2SMN1; SMN2NPC1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8440830-B2 | Tetrahydro-fused pyridines as histone deacetylase inhibitors | 4SC AG (DE) | 2013-05-14 | — | — | US | claimed |
| EP-2197552-B1 | NOVEL TETRAHYDROFUSEDPYRIDINES AS HISTONE DEACETYLASE INHIBITORS | 4SC AG (DE) | 2012-11-21 | — | — | EP | claimed |
| US-20110021494-A1 | NOVEL TETRAHYDRO-FUSED PYRIDINES AS HISTONE DEACETYLASE INHIBITORS | 4SC AG (DE) | 2011-01-27 | — | — | US | claimed |
| EP-2197552-A2 | NOVEL TETRAHYDROFUSEDPYRIDINES AS HISTONE DEACETYLASE INHIBITORS | 4SC AG (DE) | 2010-06-23 | — | — | EP | claimed |
| WO-2009037001-A2 | NOVEL TETRAHYDROFUSEDPYRIDINES AS HISTONE DEACETYLASE INHIBITORS | 4SC AG (DE) | 2009-03-26 | — | — | WO | claimed |
| US-8440830-B2 | Tetrahydro-fused pyridines as histone deacetylase inhibitors | 4SC AG (DE) | 2013-05-14 | — | — | US | disclosed |
| EP-2197552-B1 | NOVEL TETRAHYDROFUSEDPYRIDINES AS HISTONE DEACETYLASE INHIBITORS | 4SC AG (DE) | 2012-11-21 | — | — | EP | disclosed |
| US-20110021494-A1 | NOVEL TETRAHYDRO-FUSED PYRIDINES AS HISTONE DEACETYLASE INHIBITORS | 4SC AG (DE) | 2011-01-27 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110021494-A1 | NOVEL TETRAHYDRO-FUSED PYRIDINES AS HISTONE DEACETYLASE INHIBITORS | HDAC1, HDAC11, HDAC3 | TRPV1 4524/4885THRB 3429/4885NAMPT 485/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.